Edgar Filing: KING PHARMACEUTICALS INC - Form 8-K

KING PHARMACEUTICALS INC Form 8-K May 27, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 26, 2005

King Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Tennessee0 2442554-1684963(State or other jurisdiction
of incorporation)(Commission
File Number)(IRS Employer
Identification Number)

501 Fifth Street, Bristol, Tennessee (Address of principal executive offices)

37620

(Zip Code)

Registrant s telephone number, including area code: 423-989-8000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: KING PHARMACEUTICALS INC - Form 8-K

Item 8.01. Other Events

Filed as Exhibit 99.1 is a copy of the press release of King Pharmaceuticals, Inc. which was issued on May 26, 2005.

Item 9.01. Financial Statements and Exhibits

(c) Exhibits.

Exhibits:

Exhibit Number	Description of Exhibit
99.1	Press Release of King Pharmaceuticals, Inc. dated May 26, 2005.

Edgar Filing: KING PHARMACEUTICALS INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 27, 2005 KING PHARMACEUTICALS, INC.

By: /s/ James R. Lattanzi James R. Lattanzi Chief Financial Officer